bepirovirsen

News

GSK wins FDA green light for chronic hep B treatment Hibsago

GSK's antisense-based drug for chronic hepatitis B virus (HBV) infection, Hibsago, has been approved in the US, its second major market after Japan.

News

GSK hails 'unprecedented' cure rates with hep B drug

The B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.

News

GSK enlists local aid for Chinese rollout of hep B drug

GSK has partnered Sino Biopharm to make the most of the Chinese launch of hepatitis B drug bepirovirsen, currently under NMPA review.

News

GSK eyes October FDA verdict on chronic hep B drug

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.

News

GSK preps filings for chronic hepatitis B drug bepirovirsen

GSK will file its chronic hepatitis B virus therapy bepirovirsen for approval in the first quarter, after it hit the mark in two phase 3 trials.

News

FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

GSK’s antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, will get a rapid six-month review from the FDA when it is filed for approval, said the drugmaker th

GSK wins FDA green light for chronic hep B treatment Hibsago

GSK hails 'unprecedented' cure rates with hep B drug

GSK enlists local aid for Chinese rollout of hep B drug

GSK eyes October FDA verdict on chronic hep B drug

GSK preps filings for chronic hepatitis B drug bepirovirsen

FDA fast-tracks GSK’s chronic hep B therapy bepirovirsen

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

bepirovirsen

Editor's Picks